Moderna, Inc.（MRNA）今日盘中大涨7.74%，引起了市场的广泛关注。
消息面上，该股前一交易日因短期获利回吐压力出现急跌，今日买盘回补推动技术性反弹。同时，公司基本面利好仍在，其mRNA流感疫苗mFlusiva获得了美国食品药品监督管理局（FDA）顾问委员会的9-0全票推荐批准。数据显示，该疫苗在50岁以上人群中可引发强烈的免疫反应，若最终获批，将成为美国首款mRNA季节性流感疫苗。FDA的最终审批决定预计在8月初做出。
此外，公司近期已完成组织架构调整，任命了Ester Banque为首席商务官，为未来两年内可能多达三款新疫苗的上市做准备。这些积极因素共同支撑了股价的强劲表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.